Glucagon-like peptide-1 (GLP-1) receptor agonists, more commonly known as GLP-1 drugs…
Category: Obesity
Home /
From protein shakes to high-protein plans like the Paleo and Atkins…
Running 26.2 miles may not be everyone’s idea of a good…
Glucagon-like peptide (GLP-1) receptor agonists (GLP-1 RAs) are transformative medications for…
Skim the pharma news outlet of your choice, and it’s clear…
Millions of people take glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide…
In most mammals, the act of running is fueled primarily by…
The US Food and Drug Administration (FDA) has approved Rezdiffra™ (resmetirom),…
Eli Lilly has launched a new way for patients to access…
Medicare may soon face steeply increased prescription drug costs as it…
Advocates of fasting point to the potential health and longevity benefits,…
Semaglutide, under the brand names Wegovy® and Ozempic®, has surged in…
The Danish pharmaceutical company Novo Nordisk has announced promising early results…
NodThera, a biotech company based in Cambridge, England, is developing a…
As GLP-1 receptor agonist injections continue to gain acceptance as effective…
Glucagon-like peptide-1 (GLP-1) receptor agonists are arguably the hottest topic in…
Research using data from a large U.S. health survey has disrupted…
Lurking among the vast genetic holdings of the UK Biobank data,…
Gene therapy offers hope for treating a wide range of inherited…
Recent headlines have been abuzz with the groundbreaking weight loss results…
Introduction Real-world evidence (RWE) is accelerating drug development by using routinely collected patient health data, known as real-world data (RWD), to deliver insights beyond…
Introduction Researchers are developing novel, safer treatments for cancer, but bringing new oncology therapies to market is challenging. This white paper will examine the…
Introduction As global obesity rates continue to rise, the search for effective treatments is more critical than ever. Obesity is associated with an increased…
NEWARK, Del.—(BUSINESS WIRE)—QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in…
NEWARK, Del.—(BUSINESS WIRE)—QPS India, a subsidiary of QPS Holdings, LLC (QPS), a GLP/GCP-compliant global full-service Contract Research Organization, has achieved another significant milestone by…
TAIPEI, Taiwan—(BUSINESS WIRE)—QPS, a leading global contract research organization (CRO) specializing in preclinical and clinical drug development services, is pleased to announce the expansion…
Webinars
QPS and Bioanalysis Zone: Advancing Bioanalytical Method Development and Validation for Small Molecules in a Changing Regulatory Landscape
Click here to watch the webinar.
QPS and Bioanalysis Zone: Advancing Bioanalytical Method Development and Validation for Small Molecules in a Changing Regulatory Landscape
Click here to watch the webinar.
Do Weight Loss Drugs Actually Make You Healthier?
August 27, 2025
Glucagon-like peptide-1 (GLP-1) receptor agonists, more commonly known as GLP-1 drugs or GLP-1s, have skyrocketed in popularity, with usage up nearly 600 percent over six
Solving the Protein Puzzle: How Much Protein Do You Really Need?
July 7, 2025
From protein shakes to high-protein plans like the Paleo and Atkins diets, protein is all the rage for building muscle and losing weight. However, while
Got a Case of “Marathon Brain?” Research Explains Why
June 25, 2025
Running 26.2 miles may not be everyone’s idea of a good time — but marathon running is booming, with participation surging at races around the
Sight Concerns: Investigating the Link Between GLP-1 RA Medications and Eye Health
June 16, 2025
Glucagon-like peptide (GLP-1) receptor agonists (GLP-1 RAs) are transformative medications for millions of people managing diabetes and obesity. Amid research demonstrating the many benefits gained
Pharma Strikes Back at Compounding Pharmacies
March 12, 2025
Skim the pharma news outlet of your choice, and it’s clear that compounding pharmacies have been making headlines. These pharmacies typically provide one of three
Eyeing Potential Risks: Investigating Vision Changes Linked to GLP-1 Drugs
March 3, 2025
Millions of people take glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and tirzepatide to manage diabetes and obesity. These drugs have transformed weight loss and
Tiny Treadmills: Vampire Bats on the Go
January 29, 2025
In most mammals, the act of running is fueled primarily by the oxidization of carbohydrates and lipids, which are stored in the body as fuel.
Rezdiffra Gains Approval, Marks a New Chapter in Treating NASH (MASH) with Liver Scarring
November 4, 2024
The US Food and Drug Administration (FDA) has approved Rezdiffra™ (resmetirom), the first medication for treating patients with nonalcoholic steatohepatitis (NASH) with moderate to advanced
Weight Loss Drug Prescriptions Become More Accessible With Single-Dose Option
October 21, 2024
Eli Lilly has launched a new way for patients to access its popular weight loss drug, Zepbound® (tirzepatide). The company now offers single-dose vials at
Sizing Up Potential Medicare Costs of Covering Weight Loss Drugs for Heart Health
October 14, 2024
Medicare may soon face steeply increased prescription drug costs as it considers covering the popular weight loss drug, Wegovy® (semaglutide). Known for its ability to
Going Cold Turkey — How a Week-Long Fast Affects Your Health
July 31, 2024
Advocates of fasting point to the potential health and longevity benefits, often citing results from animal studies. However, the impact of prolonged calorie restriction on
Weight Loss Rebounding: The Challenges of Stopping Obesity Drugs
June 3, 2024
Semaglutide, under the brand names Wegovy® and Ozempic®, has surged in popularity for its ability to help people lose weight and reduce the risk of
Novo Nordisk Offers a New Contender in Weight Management — in Pill Form
May 20, 2024
The Danish pharmaceutical company Novo Nordisk has announced promising early results for amycretin, a novel oral weight loss medication. This new drug appears to outperform
New Class of Weight Loss Drugs Shows Promise in Treating Heart Disease
April 15, 2024
NodThera, a biotech company based in Cambridge, England, is developing a new class of medicines that inhibit the NOD-, LRR- and pyrin domain-containing protein 3
Vivani Shifts to Weight Management with an Exenatide Implant
April 1, 2024
As GLP-1 receptor agonist injections continue to gain acceptance as effective solutions for weight management and cardiovascular health, a tiny drug-delivering implant from Vivani Medical
The Link Between Obesity Drugs and Brain Health
March 6, 2024
Glucagon-like peptide-1 (GLP-1) receptor agonists are arguably the hottest topic in medical innovation. The drugs semaglutide and tirzepatide, known under brand names like Ozempic, Wegovy,
Research Challenges Conventional Wisdom on Obesity and Mortality
February 26, 2024
Research using data from a large U.S. health survey has disrupted conventional thinking about body mass index (BMI) and its role in predicting all-cause mortality.
Could Newly Identified Genetic Variant Hold the Key to Metabolic Health?
February 14, 2024
Lurking among the vast genetic holdings of the UK Biobank data, researchers uncovered a potential gem — a gene variant linked to cardiometabolic health. Conditions
Gene Therapy for Muscular Dystrophy and Obesity
December 13, 2023
Gene therapy offers hope for treating a wide range of inherited and acquired diseases and conditions, ranging from muscular dystrophy to obesity. Gene therapy for
Examining the Expanding Landscape of Weight Loss Injectables
September 25, 2023
Recent headlines have been abuzz with the groundbreaking weight loss results achieved with the injectable drug semaglutide, demonstrating the potential for people with obesity to
Introduction Real-world evidence (RWE) is accelerating drug development by using routinely collected patient health data, known as real-world data (RWD), to deliver insights beyond…
Introduction Researchers are developing novel, safer treatments for cancer, but bringing new oncology therapies to market is challenging. This white paper will examine the…
Introduction As global obesity rates continue to rise, the search for effective treatments is more critical than ever. Obesity is associated with an increased…
NEWARK, Del.—(BUSINESS WIRE)—QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in…
NEWARK, Del.—(BUSINESS WIRE)—QPS India, a subsidiary of QPS Holdings, LLC (QPS), a GLP/GCP-compliant global full-service Contract Research Organization, has achieved another significant milestone by…
TAIPEI, Taiwan—(BUSINESS WIRE)—QPS, a leading global contract research organization (CRO) specializing in preclinical and clinical drug development services, is pleased to announce the expansion…
